Healthcare ❯ Pharmaceuticals

Clinical Trials

Drug Development Drug Safety Cancer Treatment Weight Loss Drugs Pulmonary Arterial Hypertension Efficacy Studies Rare Diseases Cancer Treatments Oncology Melanoma Treatment HIV Prevention Mental Health Drug Efficacy Sanofi Phase 2 Trials Obesity Treatments Vaccine Development Phase 3 Trials Regulatory Approval Phase 2 Response Rate Drug Effectiveness Semaglutide Candidates GLP-1s Competition Phase 3 Ketamine Weight-Loss Drugs Oncology Treatments Patient Safety PrEP Mpox Treatment Compassionate Use Puberty Blockers Depression Treatments Multiple Myeloma Diabetes Treatment Neurological Conditions Drug Approval Drug Supply New Chemical Entities ALS Weight Loss Treatments Weight Management Psychedelic Research Chronic Conditions HARMONi Trials Epilepsy Treatments Metabolic Diseases Atopic Dermatitis Pulmonary Sarcoidosis Regulatory Approvals Phase II Trials Therapeutic Development Dermatology Genetic Diseases Data Security Biosimilarity Data Privacy Obesity Treatment GLP-1 Receptor Antagonists Phase 2 Studies Therapeutics RNA Therapeutics Osteogenesis Imperfecta Enzyme Replacement Therapy Patient Care Kidney Diseases Product Development Melanoma Alopecia Areata Rheumatoid Arthritis Prophylactic Treatments Regeneron Pharmaceuticals Ulcerative Colitis Experimental Drugs Psychedelic Drugs Immunotherapy GLP-1 Drugs Alzheimer's Disease Heart Disease Cardiovascular Drugs Experimental Treatments Myotonic Dystrophy

Acadia’s Alzheimer’s Psychosis Drug Misses Mid‑Stage Goal

The result increases doubt over whether the drug can show a replicable benefit in phase‑3 trials.

Aethlon Agrees to All-Stock Merger to Take North Immunology Public

Novartis’ Del‑Desiran Misses Phase III and Triggers Large Share Selloff

Capricor Faces Securities Class Action as FDA Extends Review of Duchenne Therapy

Moderna’s Phase 3 Melanoma Win Reprices the Company

BioMarin to Buy Alesta for $275 Million to Add Oral HPP Drug

Amylyx’s Avexitide Cuts Moderate‑to‑Severe Post‑Bariatric Hypoglycemia Events 55% in Phase 3

AstraZeneca Beats Q2 Estimates and Reaffirms 2026 Guidance

Late‑Stage Trial of Wainua Misses Primary Goal in ATTR‑CM Study

Definium’s Oral LSD Pill Meets Primary Endpoint in Phase 3 Depression Trial

FulcrumSec Claims 1.3TB Theft From Novo Nordisk

Gossamer Bio Hit With Investor Class Action After PROSERA Miss, With June 1 Lead‑Plaintiff Deadline

Regeneron Slides as Melanoma Combo Fails to Beat Keytruda in Phase 3

HCW Biologics Posts Surprise Q1 Profit on Trimmune Deal as Listing Risk Lingers

Cormedix Lifts 2026 Outlook After Q1 Beat, Sets H2 FDA Filing Plan for Rizzeo

Verrica Reports $5 Million Q1 Revenue as Wycanth Grows and Phase 3 Wart Program Advances

Gossamer Bio Faces Securities Class Action After PROSERA Failure, 80% Stock Plunge

Personalized mRNA Vaccine Shows Durable Survival Signal in Early Pancreatic Cancer

Law Firms Press Soleno Investors to Seek Lead Role in Securities Suit by May 5

Soleno Faces Securities Class Action Over DCCR Safety as Investors Weigh May 5 Lead‑Plaintiff Deadline